|Bid||17.39 x 800|
|Ask||17.40 x 4000|
|Day's Range||17.10 - 17.52|
|52 Week Range||13.63 - 28.60|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.15|
Nektar Therapeutics (Nasdaq: NKTR) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational agents at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Nektar Therapeutics (NASDAQ:NKTR) just released its quarterly report and things are looking bullish. The results were...
Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.